AMAG PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1981-01-01
- Employees
- 440
- Market Cap
- -
- Website
- http://www.amagpharma.com
Clinical Trials
81
Trial Phases
5 Phases
Drug Approvals
5
Clinical Trials
Distribution across different clinical trial phases (57 trials with phase data)• Click on a phase to view related trials
Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04593784
- Locations
- 🇺🇸
Qps-Mra, Llc., South Miami, Florida, United States
🇺🇸Frontage Clinical Services, Secaucus, New Jersey, United States
🇺🇸ICON Early Phase Services, LLC, San Antonio, Texas, United States
Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 228
- Registration Number
- NCT03973047
- Locations
- 🇺🇸
ICON Early Phase Serrvices, LLC, San Antonio, Texas, United States
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT03893045
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Optimus U Corporation, Miami, Florida, United States
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- Conditions
- Chronic Kidney Disease; Iron Deficiency Anemia
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 129
- Registration Number
- NCT03619850
- Locations
- 🇺🇸
Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸Wayne State University, Detroit, Michigan, United States
🇺🇸Children's Mercy Hospital, Kansas City, Missouri, United States
Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia
- Conditions
- Severe Preeclampsia
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT03008616
- Locations
- 🇺🇸
University of South Alabama, Mobile, Alabama, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸Children's Hospital Foundation Building, Louisville, Kentucky, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next